# MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

> **NCT03218163** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 1 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** MEDI-551 Maintenance

## Key facts

- **NCT ID:** NCT03218163
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-27
- **Primary completion:** 2018-04-15
- **Final completion:** 2018-04-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** MEDI-551 removed from oncology by pharmaceutical company due to change in research target.
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03218163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03218163, "MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03218163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*